Stealth Stent

We Are Innovators

The Project

Congenital Heart Diseases (CHD) affect more than 1.4 million newborns every year, and approximately 40% of these young patients require stent treatment before reaching adulthood. However, the available permanent stents are designed for adults and can trigger foreign body reaction(FBR), migration, or structural fatigue.

Our Solution

We are developing a next-generation, fully bioresorbable stent that:

Provides robust mechanical support during healing.
Dissolves safely within six months allowing vessel growth.
Features a zwitterionic polymer coating to prevent FBR.

Key Benefits

Eliminates repeat surgeries and long-term interventions.
Reduces risk of device migration and breakage.
Improves quality of life(QoL) for pediatric and adult patients alike.

Illustration of bioresorbable stent usage

About Us

We are a dedicated team combining expertise from GrOwnValve and the Biomodics consortium, united in our mission to pioneer next-generation bioresorbable medical devices that redefine patient care and drive innovation in cardiovascular treatments.

GrOwnValve

GrOwnValve is a clinical-stage medical device company developing a unique heart valve prosthesis system made from the patient’s own tissue. Our AdultValve and ChildValve, along with a bioresorbable anchoring device, provide a safe, affordable, and minimally invasive solution for valve replacement.

Biomodics

Biomodics is a pioneering Danish company specializing in advanced polymer technologies for medical devices. With a focus on precision-engineered coatings and drug delivery systems, Biomodics enhances biocompatibility and performance in cardiovascular implants. Our contributions play a critical role in enabling the next generation of resorbable stents and tissue-integrated devices.